

SOUTHERN ARCHIPELAGO LTD.

(formerly known as Blumont Group Ltd.) (Company Registration No. 199302554G) (Incorporated in the Republic of Singapore)

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2024

TABLE OF CONTENTS

Description	Page
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income	2
Condensed Interim Statements of Financial Position	3
Condensed Interim Consolidated Statement of Cash Flows	4
Condensed Interim Statements of Changes in Equity	5
Selected Notes to the Condensed Interim Consolidated Financial Statements	6
Other Information required by Listing Rule Appendix 7.2	16

Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Note		GROUP S\$'000	
		1H2024	1H2023	% Increase/ (Decrease)
Revenue	5	2,337	2,696	(13)
Other gains/(losses) - net	6	324	(154)	(310)
Interest income		10	27	(63)
Expenses				
Raw materials and consumables used		(34)	(41)	(17)
Employee benefits	7	(1,055)	(1,724)	(39)
Depreciation of property and equipment		(325)	(352)	(8)
Others	8	(857)	(619)	38
Finance costs	9	(117)	(120)	(3)
Total expenses		(2,388)	(2,856)	
Profit/(Loss) before income tax		283	(287)	
Income tax expense	10	(259)	(229)	13
PROFIT/(LOSS) FOR THE PERIOD, NET OF TAX		24	(516)	
Other comprehensive (loss)/income				
Items that may be reclassified subsequently to profit or loss: Foreign currency translation (loss)/gain				
- (Loss)/Gain on translating foreign operations		(432)	468	(192)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX		(408)	(48)	
Profit/(Loss) for the period attributable to owners of the Company		24	(516)	
Total comprehensive loss for the period attributable to owners of the Company		(408)	(48)	
Profit/(Loss) per share for the period attributable to the owners of the Company during the period (in cents)		S\$		
- Basic - Diluted		0.0001 0.0001	(0.0019) (0.0019)	

Condensed Interim Statements of Financial Position

		GROUP S\$'000		_	PANY 000
	Note	As at 30/06/2024	As at 31/12/2023	As at 30/06/2024	As at 31/12/2023
ASSETS					
Current assets Cash and bank balances		1,564	3,080	365	375
Trade and other receivables	11	466	437	21	20
Other assets	12	282	152	63	33
Income tax receivable		107	-		
		2,419	3,669	449	428
Non-current assets					
Investments in subsidiaries		-	-	91	91
Investment in associate Loans to subsidiaries	13	-	-	- 6.056	- 6 227
Property and equipment	14	6,808	4,946	6,256 155	6,227 197
Deferred tax assets	• •	287	272	-	-
		7,095	5,218	6,502	6,515
Total assets		9,514	8,887	6,951	6,943
LIABILITIES					
Current liabilities					
Trade and other payables	15	533	522	3,572	3,311
Borrowings Loan from a subsidiary	16	4,082	3,372	3,622 5,590	3,182 5,590
Lease liabilities		83	80	3,390	3,390 80
Income tax payable		_	175	-	<u>-</u> _
		4,698	4,149	12,867	12,163
Net current liabilities		(2,279)	(480)	(12,418)	(11,735)
Non-current liabilities					
Lease liabilities		66	109	66	109
Defined benefit plan	40	1,004	975	-	-
Borrowings	16	1,363 2,433	863 1,947	66	109
Total liabilities		7,131	6,096	12,933	12,272
Net assets/(liabilities)		2,383	2,791	(5,982)	(5,329)
EQUITY					
Equity attributable to owners of the Company					
Share capital	17	127,339	127,339	127,339	127,339
Reserves	18	1,084	1,516	4,619	4,619
Accumulated losses		(126,040)	(126,064)	(137,940)	(137,287)
Total equity		2,383	2,791	(5,982)	(5,329)

Condensed Interim Consolidated Statement of Cash Flows

		GROUP S\$'000	
		1H2024	1H2023
Cash Flows from Operating Activities			
Profit/(Loss) before tax		283	(287)
Adjustments for:		(07.4)	00
Unrealised foreign exchange (gain)/loss	•	(274)	86
Write-off of property and equipment	6	-	1
Depreciation of property and equipment	•	325	352
Interest expense	9	117	120
Interest income	_	(10)	(27)
Share-based payment expense	7		530
Operating cash flows before working capital changes		441	775
Changes in working capital		(4-0)	(==)
Receivables		(176)	(53)
Payables	-	53	(104)
Cash flows generated from operating activities		318	618
Tax paid		(563)	(289)
Net cash flows (used in)/generated from operating activities		(245)	329
Cash Flows from Investing Activities			
Purchase of property and equipment		(2,357)	(176)
Interest received	-	10	27
Net cash flows used in investing activities	-	(2,347)	(149)
Cash Flows from Financing Activities			
Repayment of borrowings		(171)	(3,504)
Repayments for lease liabilities		(40)	(34)
Interest paid		(102)	(655)
Proceeds from borrowings		1,425	353
Net cash flows generated from/(used in) financing activities		1,112	(3,840)
Net decrease in cash and cash equivalents	•	(1,480)	(3,660)
Cash and cash equivalents at the beginning of the period		3,080	7,344
Effect of changes in foreign exchange rates on cash and		,	
cash equivalents		(36)	(130)
Cash and cash equivalents at the end of the period	-	1,564	3,554

Condensed Interim Statements of Changes in Equity

Group

Share capital capital capital capital short reserve should reser				Attributable to o	wners of the	Company	
H2024 Balance at 1 January 2024 127,339 4,619 (4,838) 1,735 (126,064) 2,791			•				Total
Decid comprehensive loss for the period 127,339 4,619 (4,838) 1,735 (126,064) 2,791		S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Profit for the period Other comprehensive loss, net of tax: Foreign currency translation loss Total comprehensive loss for the period Balance at 30 June 2024 127,339 127,3	<u>1H2024</u>						
Other comprehensive loss, net of tax: Foreign currency translation loss - - (432) - - (432) Total comprehensive loss for the period - - - (432) - - - (432) Balance at 30 June 2024 127,339 4,619 (5,270) 1,735 (126,040) 2,383 1H2023 Balance at 1 January 2023 127,339 4,089 (4,457) 1,735 (126,077) 2,629 Loss for the period Other comprehensive income, net of tax: -	Balance at 1 January 2024	127,339	4,619	(4,838)	1,735		
tax: Foreign currency translation loss - - (432) - - (432) Total comprehensive loss for the period - - (432) - 24 (408) Balance at 30 June 2024 127,339 4,619 (5,270) 1,735 (126,040) 2,383 H2023 Balance at 1 January 2023 127,339 4,089 (4,457) 1,735 (126,077) 2,629 Loss for the period Other comprehensive income, net of tax: - - - - - - - (516) (516) Total comprehensive loss for the period Share based payment - - - 468 - - - 468 Total comprehensive loss for the period Share based payment - <th< td=""><td>•</td><td>-</td><td>-</td><td>-</td><td>-</td><td>24</td><td>24</td></th<>	•	-	-	-	-	24	24
Total comprehensive loss for the period Balance at 30 June 2024 127,339 4,619 (5,270) 1,735 (126,040) 2,383	•						
the period	,	-	-	(432)	-	-	(432)
The first of tax: Total comprehensive loss for the period Total co		-	-	(432)	-	24	(408)
Balance at 1 January 2023 127,339 4,089 (4,457) 1,735 (126,077) 2,629 Loss for the period Other comprehensive income, net of tax: Foreign currency translation gain Total comprehensive loss for the period Share based payment - - - - 468 - - - 468 - - - - 468 - - - 48)	Balance at 30 June 2024	127,339	4,619	(5,270)	1,735	(126,040)	2,383
Balance at 1 January 2023 127,339 4,089 (4,457) 1,735 (126,077) 2,629 Loss for the period Other comprehensive income, net of tax: Foreign currency translation gain Total comprehensive loss for the period Share based payment - - - - 468 - - - 468 - - - - 468 - - - 48)							
Coss for the period				/		(400 0)	
Other comprehensive income, net of tax: - 468 - - 468 Foreign currency translation gain - - 468 - - 468 Total comprehensive loss for the period - - 468 - (516) (48) Share based payment - 530 - - - 530	•	127,339	4,089	(4,457)	1,735	\ ' '	
of tax: - - 468 - - 468 Total comprehensive loss for the period - - - 468 - (516) (48) Share based payment - 530 - - - 530	•	-	-	-	-	(516)	(516)
Total comprehensive loss for the period 468 - (516) (48) Share based payment - 530 530	•						
the period	Foreign currency translation gain	-	-	468	-	-	468
Share based payment - 530 530		-	-	468	-	(516)	(48)
Balance at 30 June 2023 127,339 4,619 (3,989) 1,735 (126,593) 3,111	-		530				530
	Balance at 30 June 2023	127,339	4,619	(3,989)	1,735	(126,593)	3,111

Company

	Share capital S\$'000	Share option reserve S\$'000	Accumulated losses S\$'000	Total S\$'000
<u>1H2024</u>				
Balance at 1 January 2024	127,339	4,619	(137,287)	(5,329)
Loss for the period	-	-	(653)	(653)
Total comprehensive loss for the period	-	-	(653)	(653)
Balance at 30 June 2024	127,339	4,619	(137,940)	(5,982)
1H2023				
Balance at 1 January 2023	127,339	4,089	(136,102)	(4,674)
Loss for the period	-	-	(1,192)	(1,192)
Total comprehensive loss for the period	-	-	(1,192)	(1,192)
Share based payment	-	530	-	530
Balance at 30 June 2023	127,339	4,619	(137,294)	(5,336)

SELECTED NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate Information

Southern Archipelago Ltd. (formerly known as Blumont Group Ltd.) (the "Company") is a public limited company incorporated and domiciled in Singapore and is listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX-ST"). These condensed interim consolidated financial statements as at and for the six-month ended 30 June 2024 comprise the Company and its subsidiaries (collectively, the "Group").

The principal activity of the Company is that of investment holding. The principal activities of its subsidiaries are sterilisation and polymerisation services, hospitality management and property development.

2. Basis of Preparation

The condensed interim financial statements for the six months ended 30 June 2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("SFRS(I)") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2023.

The accounting policies adopted by the Group are consistent with those used in its most recent audited financial statements, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore Dollars ("S\$"), which is the functional currency of the Company.

As at 30 June 2024, the Group and Company are in a net current liability position of \$\$2,279,000 and \$\$12,418,000 (which includes a loan from a 100% owned subsidiary of \$\$5,590,000) respectively. This condition may cast significant doubt on the ability of the Group and Company to continue as a going concern and to realise its assets and discharge its liabilities in the ordinary course of business. Nevertheless, the directors of the Group and Company believe that the use of the going concern assumption in the preparation and presentation of the financial statements for the financial period ended 30 June 2024 remains appropriate after taking into account the following factors:

- The Group expects the sterilisation business segment to continue generating positive operating cash flows in the next 12 months. In addition, the Group's sterilisation business segment is in the process of expanding its business capacity and expect the business to continue to grow and generate positive operating cashflow;
- The Board and management continue to explore business opportunities through acquisitions joint ventures, strategic
 alliances and foster partnerships with various third parties in the industries to undertake the hospitality and wellness
 businesses; and
- The Board and the management are currently exploring possible fundraising options to secure financing commitments to allow the Company to have access to additional working capital where required, including but not limited to bank loans, additional shareholders' loan, extension of shareholder's loan and loan from subsidiaries and fund raising from its shareholders.

Management has assessed the cash flow forecasts of the Group and Company for the next 12 months and concluded that there will be sufficient cash flows and resources to allow the Group and Company to continue its operations and meet its obligations for the foreseeable future. The Board has assessed the ability of the Group and Company to meet its short-term obligations as and when it falls due and is also of the opinion that the Group and Company will be able to raise the necessary funds for its working capital purposes when required.

2.1 New and Amended Standards Adopted by the Group

The adoption of various new/revised SFRS(I)s effective for the financial year beginning on 1 January 2024 does not have a material financial effect on the Group and the Company.

2.2 Use of Judgements and Estimates

In preparing the condensed interim financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2023.

2.2 Use of Judgements and Estimates (con't)

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

(a) Critical judgments in applying accounting policies

The application of judgments in the process of applying the Group's accounting policies that are expected to have a significant effect on the amounts recognised in the financial statements are as follows:

(i) Impairment of investments in subsidiaries

Investments in subsidiaries (including loans to subsidiaries which are in substance part of the net investments in subsidiaries) are tested for impairment whenever there is any objective evidence or indication that these investments may be impaired. In determining whether there is objective evidence of impairment, the Company considers factors such as the subsidiaries' financial performance, financial position and the overall economic environment in which the subsidiaries operate.

(ii) Impairment of investment in an associate

Investment in an associate is tested for impairment whenever there is any objective evidence or indication that the investment may be impaired. The recoverable amount of the investment in an associate is determined based on the higher of fair value less costs of disposal and value in use.

(iii) Loss allowance for trade receivables

The Group measures the loss allowance for trade receivables at an amount equal to lifetime expected credit losses ("ECLs"). The ECLs on trade receivables are estimated using a provision matrix which involves grouping receivables according to historical loss patterns (e.g. customer rating or by geographical location) and applying a historic provision rate which is based on days past due for groupings of various customer segments that have similar loss patterns. In devising such a provision matrix, the Group uses its historical credit loss experience with forward-looking information (adjusted as necessary to reflect current conditions and forecast economic conditions) to estimate the lifetime expected credit losses on the trade receivables. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

(iv) Income taxes

The Group is subject to income taxes in numerous jurisdictions. In determining the income tax liabilities, management is required to estimate the amount of capital allowances, deductibility of certain expenses and taxability of certain income in each relevant tax jurisdictions. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Group recognises liabilities based on estimates of whether additional taxes will be due. Where the final tax outcome is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

2.2 Use of Judgements and Estimates (con't)

(b) Key sources of estimation uncertainty

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty as at the statement of financial position date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year:

(i) Defined benefit plan

The present value of employee compensation depends on a number of factors that are determined on an actuarial basis using a number of assumptions. The assumptions used include the discount rate, rate of future salary increase and rate of resignation. Any changes in these assumptions will impact the carrying amount of employee compensation.

In determining the appropriate discount rate, management considers the interest rates of high-quality corporate bonds with extrapolated maturities corresponding to the expected duration of the defined benefit obligations. These corporate bonds generally have an AA rating with low risk of default. The interest rate is used to determine the present value of estimated future cash outflows expected to be required to settle employee compensation. Management does not expect any variable changes in the assumptions used to determine the present value of employee compensation on an actuarial basis will result in the amount determined to be materially different.

The Group obtains external, independent actuarial report annually. The actuarial gain/(loss) will be assessed during year end.

3. Seasonal Operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and Revenue Information

The Group is organised into four main business segments:

- Investment holding investment in transferable securities including but not limited to marketable shares, warrants and debentures etc.
- Sterilisation providing contract sterilisation and polymerisation services to food packaging, medical devices, cosmetic raw materials and consumers products.
- Property long-term holding of properties for rental and related income.
- Hospitality and wellness provision of hotel management and wellness services.

4.1 Reportable Segments

	holding		and wellness		
1 January 2024 to 30 June 2024	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
External revenues		2,337	-	-	2,337
Segment results	(649)	1,373	(7)	(2)	715
Interest income	_*	10	-	-	10
Finance costs	(79)	(38)	-	-	(117)
Depreciation	(43)	(282)	-	-	(325)
Reportable segment (loss)/profit before income tax	(771)	1,063	(7)	(2)	283
Other material item					
Capital expenditure					
- property and equipment	1	2,356	-	-	2,357
Segment assets	691	8,513	7	16	9,227
Unallocated assets – deferred tax assets					287
Consolidated total assets				-	9,514
Segment liabilities	4,274	2,849	3	5	7,131
Consolidated total liabilities *: < \$\$1,000				-	7,131
. \ 3\pi1,000					
	Investment	Sterilisation	Hospitality	Property	Total
1 January 2023 to 30 June 2023	holding		and wellness		
1 January 2023 to 30 June 2023 External revenues		Sterilisation S\$'000 2,696	•	Property S\$'000	S\$'000
External revenues	holding S\$'000 	S\$'000 2,696	and wellness S\$'000		
-	holding	S\$'000	and wellness	S\$'000 -	S\$'000 2,696
External revenues Segment results	holding \$\$'000 - (1,264)	\$\$'000 2,696 1,213	and wellness S\$'000	S\$'000 -	\$\$'000 2,696 158
External revenues Segment results Interest income	holding \$\$'000 - (1,264) 6	\$\$'000 2,696 1,213 21	and wellness S\$'000	S\$'000 -	\$\$'000 2,696 158 27
External revenues Segment results Interest income Finance costs	holding \$\$'000 	\$\$'000 2,696 1,213 21 (46)	and wellness S\$'000	S\$'000 -	\$\$'000 2,696 158 27 (120)
External revenues Segment results Interest income Finance costs Depreciation	holding \$\$'000 - (1,264) 6 (74) (42)	\$\$'000 2,696 1,213 21 (46) (310)	and wellness \$\$'000 	\$\$'000 - 214 - -	\$\$'000 2,696 158 27 (120) (352)
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item	holding \$\$'000 - (1,264) 6 (74) (42)	\$\$'000 2,696 1,213 21 (46) (310)	and wellness \$\$'000 	\$\$'000 - 214 - -	\$\$'000 2,696 158 27 (120) (352)
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax	holding \$\$'000 - (1,264) 6 (74) (42)	\$\$'000 2,696 1,213 21 (46) (310)	and wellness \$\$'000 	\$\$'000 - 214 - -	\$\$'000 2,696 158 27 (120) (352)
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item Capital expenditure	holding S\$'000 	\$\$'000 2,696 1,213 21 (46) (310) 878	and wellness \$\$'000 	\$\$'000 - 214 - -	\$\$'000 2,696 158 27 (120) (352) (287)
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item Capital expenditure - property and equipment	holding S\$'000 (1,264) 6 (74) (42) (1,374)	\$\$'000 2,696 1,213 21 (46) (310) 878	and wellness \$\$'000 - (5) - - (5)	\$\$'000 - 214 - - - 214	\$\$'000 2,696 158 27 (120) (352) (287)
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item Capital expenditure - property and equipment Segment assets	holding S\$'000 (1,264) 6 (74) (42) (1,374)	\$\$'000 2,696 1,213 21 (46) (310) 878	and wellness \$\$'000 - (5) - - (5)	\$\$'000 - 214 - - - 214	\$\$'000 2,696 158 27 (120) (352) (287) 407 9,045
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item Capital expenditure - property and equipment Segment assets Unallocated assets – deferred tax assets	holding S\$'000 (1,264) 6 (74) (42) (1,374)	\$\$'000 2,696 1,213 21 (46) (310) 878	and wellness \$\$'000 - (5) - - (5)	\$\$'000 - 214 - - - 214	\$\$'000 2,696 158 27 (120) (352) (287) 407 9,045 274
External revenues Segment results Interest income Finance costs Depreciation Reportable segment (loss)/profit before income tax Other material item Capital expenditure - property and equipment Segment assets Unallocated assets – deferred tax assets Consolidated total assets	holding \$\$'000 	\$\$'000 2,696 1,213 21 (46) (310) 878 172 7,773	and wellness \$\$'000 - (5) - - (5)	\$\$'000 - 214 - - - 214	\$\$'000 2,696 158 27 (120) (352) (287) 407 9,045 274 9,319

Investment Sterilisation Hospitality

Property

Total

4.2 Geographical Information

Singapore

Indonesia

As at 30 June 2024	External Revenues S\$'000	Non-current assets^^ S\$'000	
Singapore	-	155	
Indonesia	2,337	6,653	
	2,337	6,808	
As at 30 June 2023	External Revenues	Non-current assets^^	

S\$'000

2,696

2,696

In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers. Segment assets are based on the geographical location of the assets.

5. Revenue

	Gro	Group		
	6 months ended 30 Jun 2024 S\$'000	6 months ended 30 Jun 2023 S\$'000		
Revenue from sterilisation services	2,337	2,696		

The Group derives revenue from the transfer of services at a point in time. The Group satisfies a performance obligation when the customers receive the services.

6. Other Gains/(Losses) - Net

	Grou	др
	<u>6 months</u>	6 months
	<u>ended</u>	<u>ended</u>
	<u>30 Jun 2024</u>	30 Jun 2023
	S\$'000	S\$'000
Currency exchange gain/(loss) – net	307	(178)
Loss on property and equipment written off	-	(1)
Miscellaneous income	17	25
	324	(154)

S\$'000

240

4,183

4,423

^{^^ :} Non-current assets exclude deferred tax assets

7. Employee Benefits

	Group		
	<u>6 months</u> ended	6 months ended	
	30 Jun 2024 S\$'000	30 Jun 2023 S\$'000	
Short-term employee benefits	963	1,091	
Contribution to defined contribution plans	21	19	
Defined benefits plans	71	84	
Share-based payment expense		530	
	1,055	1,724	
Comprised:			
Directors of the Company	169	320	
Directors of the Group's subsidiaries	160	183	

8. Other Expenses

	<u>6 months</u> ended	6 months ended
	30 Jun 2024	30 Jun 2023
Audit fees:	S\$'000	S\$'000
- auditor of the Company	47	40
- other auditors	4	5
Loss allowance on trade receivables	-	5
Legal, professional and consultancy fees	75	58
Upkeep expenses	57	105
Directors' fees	52	52
Travelling expenses	56	50
Postage and telecommunication expenses	7	8
Printing and stationery expenses	16	7
Staff training and welfare expenses	65	40
Marketing and advertising	10	16
Provision for withholding tax expense	51	51
Sundry expenses	1	1
SGX expenses	18	18
Expenses incurred for disposal of cobalt waste	126	_
Others	272	163
	857	619

9. Finance Costs

	Group		
	6 months	6 months	
	ended	ended	
	<u>30 Jun 2024</u> S\$'000	30 Jun 2023 S\$'000	
Interest expense	οψ σσσ	Οψ 000	
- loans from banks	97	102	
- loans from shareholders	16	14	
- lease liabilities	4	4	
	117	120	

Group

10. Income Tax Expense

The Group calculates the income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Grou	Group		
	<u>6 months</u> <u>ended</u> <u>30 Jun 2024</u> S\$'000	6 months ended 30 Jun 2023 S\$'000		
Income tax expense comprised:				
Current income tax expense	282	226		
Deferred tax	(23)	3		
	259	229		

11. Trade and Other Receivables

	Group		Company	
	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000
Trade receivables - third parties (a) Less: Loss allowance	305 -*	278 (5)		-
Trade receivables - net	305	273	-	<u>-</u>
Other receivables - third parties	161	164	21	20
Total trade and other receivables *: < \$\$1,000	466	437	21	20

⁽a) Trade receivables from third parties are non-interest bearing and repayable within the normal trade credit terms of 30 to 60 days (2023: 30 to 60 days).

12. Other Assets

	Group		Company	
	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000
Deposits	26	26	24	24
Prepayments	256	126	39	9
Total other assets	282	152	63	33

13. Investment in Associate

	Group		Company	
	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000
Balance at the beginning of the period/year Share of loss of associate	364 (259)	594 (230)	729 -	729 -
Balance at the end of the period/year Less: Allowance for	105	364	729	729
impairment loss	(105)	(364)	(729)	(729)

As at 30 June 2024, the Group and the Company has fully impaired its investment in an associate to profit or loss, the recoverable amount of which was determined to be S\$Nil on the basis that the associate is in a net total liability position as at 30 June 2024.

14. Property and Equipment

During the six months ended 30 June 2024, the Group acquired assets amounting to \$\$2,357,000 (30 June 2023: \$\$407,000).

15. Trade and Other Payables

	Group		Company	
	As at 30 Jun 2024	As at 31 Dec 2023	As at 30 Jun 2024	As at 31 Dec 2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Other payables	26	54	26	51
Deposit payable	*	*	-	-
Interest payable (a)	202	186	3,283	3,011
Amount due to directors	31	-	31	-
Accrued operating expenses	274	282	232	249
Total trade and other payables	533	522	3,572	3,311
*: < S\$1,000				

⁽a) Interest payable relates to loan from a shareholder and loan from a subsidiary.

16. Borrowings

	Group		Company	
	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000
Current				
Secured - Loans from bank (a)	460	190	-	-
Unsecured - Loans from bank (b) Unsecured - Loans from	1,750	1,800	1,750	1,800
shareholders (c)	1,872	1,382	1,872	1,382
	4,082	3,372	3,622	3,182
Non-current				
Secured - Loans from bank (a)	1,363	863	-	<u> </u>
Total borrowings	5,445	4,235	3,622	3,182

⁽a) Loans from banks are secured over the Group's freehold land and building. The loans from banks bear an interest of 7.75% (2023: between 8.0% and 9.0%) per annum.

⁽b) Loans from banks are unsecured and bears interest of 2.5% plus bank's Cost of Funds.

⁽c) Loans from shareholders are unsecured and bears interest of between 2% to 4.5% per annum and 4.65% per week (2023: 2% per annum).

17. Share Capital

Group	and	Company	
-------	-----	---------	--

	Group and Company			
	As at 30 Jun	e 2024	As at 31 Dec	<u> 2023</u>
	Number of		Number of	
	ordinary shares	S\$'000	ordinary shares	S\$'000
Beginning and end of	•		•	
period/year	27,570,762,183	127,339	27,570,762,183	127,339

The Company did not hold any treasury shares as at 30 June 2024 and 31 December 2023.

The Company's subsidiaries do not hold any shares in the Company as at 30 June 2024 and 31 December 2023.

Blumont Employee Share Option Scheme 2013 (the "Blumont ESOS 2013")

The Company announced that on 17 June 2021, the Company has made grants of options in respect of ordinary shares in the capital of the Company pursuant to the Company's Employee Share Option Scheme 2013 to various persons. Total number of shares under Options granted is 1,160,000,00 which 580,000,000 were granted as Market Price Options of \$\$0.004 per ordinary share and 580,000,000 were granted as Discounted Options of \$\$0.0032 per ordinary share. The grant and exercise of these Options under the Blumont ESOS 2013 are subjected to the acceptances of the various persons granted the Options under the Blumont ESOS 2013.

As at 30 June 2024, Blumont ESOS 2013 has expired and there were outstanding options for conversion into 1,160,000,00 (31 Dec 2023: 1,160,000,00) ordinary shares.

Southern Archipelago Employee Share Option Scheme 2023 ("SAL ESOS 2023") and Performance Share Plan 2023 ("SAL PSP 2023")

No share options under the SAL ESOS 2023 and incentive share awards under the SAL PSP 2023 have been granted for the six months ended 30 June 2024 (31 Dec 2023: Nil).

18. Reserves

	Group		Company	
	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000	As at 30 Jun 2024 S\$'000	As at 31 Dec 2023 S\$'000
Composition:				
Currency translation reserve	(5,270)	(4,838)	-	-
Other reserves	1,735	1,735	-	-
Share option reserve	4,619	4,619	4,619	4,619
	1,084	1,516	4,619	4,619

19. Related Party Transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

20. Financial Assets and Financial Liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group and the Company as at 30 June 2024 and 31 December 2023.

	Group		Company		
	As at 30 Jun 2024	As at 31 Dec 2023	As at 30 Jun 2024	As at 31 Dec 2023	
	S\$'000	S\$'000	S\$'000	S\$'000	
Financial assets					
At amortised cost Cash and bank balances Trade and other receivables Loans to subsidiaries Other assets (deposits) Total	1,564	3,080	365	375	
	466	437	21	20	
	-	-	6,256	6,227	
	26	26	24	24	
	2,056	3,543	6,666	6,646	
Financial liabilities					
At amortised cost Trade and other payables Borrowings Loan from a subsidiary Lease liabilities Total	533	522	3,572	3,311	
	5,445	4,235	3,622	3,182	
	-	-	5,590	5,590	
	149	189	149	189	
	6,127	4,946	12,933	12,272	

21. Net Asset/(Liability) Value Per Ordinary Share

	Group		Company	
	As at 30 Jun 2024	As at 31 Dec 2023	As at 30 Jun 2024	As at 31 Dec 2023
Net asset/(liability) value per ordinary share (in				
cents)	0.009	0.0101	(0.022)	(0.0193)

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2

1. Review

The condensed consolidated statement of financial position of Southern Archipelago Ltd. (formerly known as Blumont Group Ltd.) and its subsidiaries as at 30 June 2024 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-months period then ended and certain explanatory notes have not been audited or reviewed.

2. Review of Performance of the Group

Commentary on the Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income

Revenue

Revenue decreased by S\$0.36 million to S\$2.34 million for 1H2024 (1H2023: S\$2.70 million), mainly due to reduced cobalt activity of the sterilisation segment of the Group.

Other Gains/(Losses) - Net

Other gains/(losses) increased by S\$0.47 million to gains of S\$0.32 million for 1H2024 (1H2023: losses of S\$0.15 million), mainly due to currency exchange gain recognised during the reporting period.

Interest Income

Interest income decreased by S\$17,000 to S\$10,000 for 1H2024 (1H2023: S\$27,000) mainly due to lower bank balance held in interest earning bank accounts.

Expenses

Raw materials and consumables used decreased by \$\$7,000 to \$\$34,000 in 1H2024 (1H2023: \$\$41,000). The decrease in raw materials and consumables used were in line with the reduced revenue from the sterilisation segment.

Employee benefits expenses decreased by \$\$0.66 million to \$\$1.06 million in 1H2024 (1H2023: \$\$1.72 million), mainly due to nil share-based payment expense recognised during the reporting period.

Other expenses increased by S\$0.24 million to S\$0.86 million in 1H2024 (1H2023: S\$0.62 million), mainly due to fees and duty charges for the disposal of cobalt waste incurred during the reporting period.

Income Tax Expenses

Income tax expenses increased by \$\$0.03 million to \$\$0.26 million in 1H2024 (1H2023: \$\$0.23 million), mainly due to higher chargeable income for sterilisation business during the reporting period. The Group will review and assess the annual income tax expenses at year end.

Other Comprehensive Income

Foreign currency translation loss on translating foreign operations of S\$0.43 million for 1H2024 (1H2023: gain of S\$0.47 million) relates to the translation of the results and the net assets of the Group's foreign operations from their functional currencies to the Group's presentation currency in accordance with SFRS(I) 1-21 *The Effects of Changes in Foreign Exchange Rate*.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2 (Cont'd)

Commentary on the Condensed Interim Statement of Financial Position

Cash and bank balances decreased by S\$1.52 million or 49% from S\$3.08 million as at 31 December 2023 to S\$1.56 million as at 30 June 2024, mainly due to payment made for new cobalt rods and ongoing construction for the expansion of the sterilisation business.

Other assets increased by S\$0.13 million or 87% from S\$0.15 million as at 31 December 2023 to S\$0.28 million as at 30 June 2024, mainly due to prepayments made by the sterilisation business for the purchase of equipment.

Current income tax liabilities decreased by S\$0.29 million or 161% from income tax payable of S\$0.18 million as at 31 December 2023 to income tax receivable of S\$0.11 million at as 30 June 2024, mainly due to VAT refundable from the purchase of new cobalt rods.

Property and equipment increased by \$\$1.86 million or 38% from \$\$4.95 million as at 31 December 2023 to \$\$6.81 million as at 30 June 2024, mainly due to purchase of new cobalt rods and construction in progress recognised for the expansion of sterilisation business.

Borrowings, including current and non-current, increased by \$\\$1.21 million or 29\% from \$\\$4.24 million as at 31 December 2023 to \$\\$5.45 million as at 30 June 2024, mainly due to additional bank loans and shareholders loans taken up.

Lease liabilities, including current and non-current, decreased by \$\$0.04 million or 21% from \$\$0.19 million as at 31 December 2023 to \$\$0.15 million as at 30 June 2024, mainly due to repayment of lease liabilities.

As at 30 June 2024, the Group had a negative working capital of S\$2.28 million (31 December 2023: S\$0.48 million). The Company intends to fund its operation through the Group's internal resources, loans from shareholder, borrowings and/or capital raising as and when required.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as there is no forecast or prospect statement previously disclosed to shareholders.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

Below are updates on the Group's operations:

Sterilisation

The sterilisation business is expected to improve in the second half of 2024 due to the replacement of cobalt rods in end June 2024 which will result in an increase to the segment's sales capacity.

In addition, the Group's sterilisation business segment is in the process of expanding its business capacity. The management expects the sterilisation business will continue to grow and generate positive operating cashflow

5. Dividend Information

(a) Current Financial Period Reported On.

Any dividend declared for the current financial period reported on? No.

(b) Corresponding Period of the Immediately Preceding Financial Year.

Any dividend declared for the corresponding period of the immediately preceding financial year?

(c) Date payable

Not applicable.

(d) Books closure date

Not applicable.

(e) If no dividend has been declared/recommended, a statement to that effect.

The Board of Directors does not recommend any payment of dividends for the six months ended 30 June 2024.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2 (Cont'd)

6. General Mandate from Shareholders for Interested Party Transactions

No general mandate for Interested Party Transactions has been obtained from the shareholders.

7. Confirmation pursuant to Rule 705(5) of the listing manual.

To the best of our knowledge, nothing has come to the attention of the Board of Directors which may render the unaudited consolidated financial results for the six months ended 30 June 2024 to be false or misleading.

On behalf of the Board of Directors

Alan Chin Yu Ng Keok Chai

Executive Director Lead Independent Director

8. Confirmation Pursuant to Rule 720(1) of the listing manual.

The Company hereby confirms that it has procured undertakings from all its directors and executive officer under Rule 720(1) of the listing manual.

BY ORDER OF THE BOARD Southern Archipelago Ltd.

John Lee Yow Meng Chief Financial Officer and Executive Director 13 August 2024